LSE - Delayed Quote USD

AstraZeneca PLC (0A4J.L)

75.42 +0.21 (+0.28%)
At close: April 26 at 7:02 PM GMT+1
Key Events
Advanced Chart
Loading Chart for 0A4J.L
DELL
  • Previous Close 75.21
  • Open 74.99
  • Bid --
  • Ask --
  • Day's Range 74.66 - 75.42
  • 52 Week Range 60.47 - 76.43
  • Volume 22,035
  • Avg. Volume 91,191
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.36
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 71.90

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

www.astrazeneca.com

89,900

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

More about AstraZeneca PLC

Recent News: 0A4J.L

View More
View More

Related Videos: 0A4J.L

AstraZeneca reinforcing supply chain amid global tensions: CEO

AstraZeneca shares (AZN) revealed a first-quarter earnings beat on Thursday, posting revenue of $12.68 billion, a 19% year-over-year gain. In addition, the pharmaceutical giant has reiterated its full-year guidance by claiming its "core EPS is expected to increase by a low double-digit to low teens percentage." To keep that guidance, the company bolstered its drug production, particularly in China, as uncertainty caused by geopolitical conflicts gave cause for concern. Shares of the pharmaceutical giant are rising on this news. AstraZeneca CEO Pascal Soriot joins Yahoo Finance Health Reporter Anjalee Khemlani to discuss AstraZeneca's performance, its production abilities, and future cancer treatments. "We are very much engaged in China, and we have been for many, many years. Having said that, of course, we have considered all this geopolitical tensions, and we have established a very resilient supply chain. We have manufacturing sites in China for China and some other countries in the emerging markets, in particular," Soriot speaks on the company's international ties. "Aand of course, we have a supply chain that is dedicated to what you might call the Western world — the US and Europe, for instance. We are right now in the process of building a cell therapy manufacturing site in Maryland. So, we really have a very resilient supply chain that has shown that it can sustain a crisis, and the COVID was a good example of this. " For more expert insight and the latest market action, click here to watch this full episode. This post was written by Nicholas Jacobino
Yahoo Finance Video · yesterday
AZNCF
AZN

Performance Overview: 0A4J.L

Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

0A4J.L
13.79%
MSCI WORLD
5.23%

1-Year Return

0A4J.L
4.74%
MSCI WORLD
19.98%

3-Year Return

0A4J.L
49.11%
MSCI WORLD
12.82%

5-Year Return

0A4J.L
0.00%
MSCI WORLD
53.42%

Compare To: 0A4J.L

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

0A4J.L
AstraZeneca PLC
75.42
+0.28%
Mkt Cap -
Industry -

Statistics: 0A4J.L

View More

Valuation Measures

Annual
As of

  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.30%

  • Return on Assets (ttm)

    7.04%

  • Return on Equity (ttm)

    17.29%

  • Revenue (ttm)

    47.61B

  • Net Income Avi to Common (ttm)

    6.33B

  • Diluted EPS (ttm)

    -0.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.02B

  • Total Debt/Equity (mrq)

    92.51%

  • Levered Free Cash Flow (ttm)

    8.68B

View More

Research Analysis: 0A4J.L

View More

Analyst Price Targets

54.50 Low
71.90 Average
75.42 Current
80.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 
View More

Company Insights: 0A4J.L

People Also Watch

0A1K.L NIO Inc.
4.4200
+7.02%
 
0O87.IL Telefonaktiebolaget LM Ericsson (publ)
57.55
+0.12%
 
0AB9.L Daimler Truck Holding AG
42.11
+0.38%
 
0DNH.IL Atos SE
1.8793
-0.42%
 
0AAE.IL AutoStore Holdings Ltd.
40.00
0.00%
 
0B67.IL Galp Energia, SGPS, S.A.
20.63
+2.07%
 
0AAS.IL Samhällsbyggnadsbolaget i Norden AB (publ)
48.62
0.00%
 
SYN.L Synergia Energy Ltd
0.1275
+6.25%
 
0A9L.L AUTO1 Group SE
4.8940
+4.18%
 
0A28.IL Prosus N.V.
31.41
+0.61%
 
0BJP.IL Webuild S.p.A.
2.2900
+6.17%
 
0H0G.IL Sweco AB (publ)
116.00
+3.11%
 
0A0H.IL Beijer Ref AB (publ)
133.70
0.00%
 
0GT1.IL Castellum AB (publ)
128.93
+2.67%
 
0FIN.IL Orkla ASA
73.90
+0.07%
 
0GFE.L Embracer Group AB (publ)
27.16
-1.70%